scholarly journals European stakeholder perspectives on challenges to rare disease drug development – a qualitative study

Author(s):  
Sarala Joshi ◽  
Jessica Chen ◽  
Mustafa Sultan ◽  
Shefali Singh ◽  
Syed Abedi ◽  
...  
2021 ◽  
Vol 16 ◽  
Author(s):  
Erica Winter ◽  
Scott Schliebner

: Characterized by small, highly heterogeneous patient populations, rare disease trials magnify the challenges often encountered in traditional clinical trials. In recent years, there have been increased efforts by stakeholders to improve drug development in rare diseases through novel approaches to clinical trial designs and statistical analyses. We highlight and discuss some of the current and emerging approaches aimed at overcoming challenges in rare disease clinical trials, with a focus on the ultimate stakeholder, the patient.


2018 ◽  
Vol 29 (6) ◽  
pp. 889-899 ◽  
Author(s):  
Yannick Le Hénaff ◽  
Stéphane Héas ◽  
Pascal Joly

This qualitative study conducted in France of “individuals living with a pemphigus” (ILPs; N = 54) highlights the taxing diagnostic trajectory of those suffering from these rare autoimmune diseases. Beyond enduring a diagnostic period that may prove long, during their numerous medical appointments, these individuals internalize the expectations of the medical professionals who are treating them. In some cases, numerous inconclusive medical tests and, at times, a doctor’s condescension may push the patient toward a process of renunciation. This article relates the ILPs’ critiques of the medical work conducted during the trying diagnostic period.


Author(s):  
Vanessa L. Merker ◽  
Scott R. Plotkin ◽  
Martin P. Charns ◽  
Mark Meterko ◽  
Justin T. Jordan ◽  
...  

BMJ Open ◽  
2016 ◽  
Vol 6 (2) ◽  
pp. e010246 ◽  
Author(s):  
K L Mattick ◽  
K Kaufhold ◽  
N Kelly ◽  
J A Cole ◽  
G Scheffler ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document